Skip to main
  1. Stocks
  2. Blossomhill Therapeutics Inc
  3. Forecast
BLSM

BLSM Stock Forecast & Price Target

BLSM Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BlossomHill Therapeutics is attractive because its lead BH-30643 is already showing differentiated clinical activity in a large, clinically validated EGFR-mutant NSCLC market, with 53% partial responses in 34 evaluable C797S+ patients and 78% ORR in 27 TKI-naive classical EGFR+ patients, while remaining well-tolerated and CNS-active. The company’s pipeline is further de-risked by BH-30236, which has shown early anti-leukemic activity in R/R AML and HR-MDS, including 28.6% with ≥50% marrow blast reductions, a 36% ORR in 11 evaluable R/R AML patients, and manageable dosing, supporting a second credible franchise in a high-unmet-need setting. Financially, BlossomHill ended 2Q26 with about $95 million in cash and equivalents and added $168.3 million from its August 2026 IPO, implying runway into 2Q28 and giving it time to reach key readouts in 1Q27 and 2027.

Bears say

BlossomHill Therapeutics is a pre-profit clinical-stage biotech with no assurance it will ever generate earnings, and the need to raise additional capital remains a material risk if development costs continue to rise. Its lead asset BH-30643 also appears to face a difficult competitive and regulatory path, with safety concerns centered on hepatotoxicity, including treatment-related Grade ≥3 ALT elevations in 7.1% of patients and Grade 3 AST elevations in 4.6%, which may limit differentiation versus established EGFR therapies. Beyond BH-30643, the broader pipeline is still unproven, as the company’s second clinical program and preclinical KRAS asset have not yet established proof of concept, leaving fundamental value highly dependent on uncertain clinical data.

BLSM has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Blossomhill Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

BLSM Analyst Forecast & Price Prediction

Get the latest BLSM stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BLSM

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Blossomhill Therapeutics Inc (BLSM) Forecast

Analysts have given BLSM a Buy based on their latest research and market trends.

According to 5 analysts, BLSM has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Blossomhill Therapeutics Inc (BLSM)


BLSM Analyst Forecast & Price Prediction

Get the latest BLSM stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BLSM

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BLSM stock data and trends